Priyank Desai

Priyank Desai

Auto-generated profile, based on publicly available information

Priyank Desai

American University of Saint Vincent School of Medicine, Kingstown, Saint Vincent and the Grenadines

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Open access
PDF file
Adekunle SanyaoluAdekunle Sanyaolu
Adekunle Sanyaolu
COChuku Okorie
Chuku Okorie
AMAleksandra Marinkovic
Aleksandra Marinkovic
RPRisha Patidar
Risha Patidar
KYKokab Younis
Kokab Younis
MAMohsin Altaf
Mohsin Altaf
A novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in Wuhan, China, in December 2019. Since then, the virus has made its way across the globe to affect over 180 countries. SARS-CoV-2 has infected humans in all age groups, of all ethnicities, both males and females while spreading through communities at an alarming rate. Given the nature of this virus, there is much still to be learned; however, we know that the clinical manifestations range from a common cold to more severe diseases such as bronchitis, pneumonia, severe acute respiratory distress syndrome (ARDS), multi-organ failure, and even death. It is believed that COVID-19, in those with underlying health conditions or comorbidities, has an increasingly rapid and severe progression, often leading to death. This paper examined the comorbid conditions, the progression of the disease, and mortality rates in patients of all ages, infected with the ongoing COVID-19 disease. An electronic literature review search was performed, and applicable data was then collected from peer-reviewed articles published from January to April 20, 2020. From what is known at the moment, patients with COVID-19 disease who have comorbidities, such as hypertension or diabetes mellitus, are more likely to develop a more severe course and progression of the disease. Furthermore, older patients, especially those 65 years old and above who have comorbidities and are infected, have an increased admission rate into the intensive care unit (ICU) and mortality from the COVID-19 disease. Patients with comorbidities should take all necessary precautions to avoid getting infected with SARS CoV-2, as they usually have the worst prognosis.

1 January 2022 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
Adekunle SanyaoluAdekunle Sanyaolu
Adekunle Sanyaolu
AMAleksandra Marinkovic
Aleksandra Marinkovic
SPStephanie Prakash
Stephanie Prakash
PDPriyank Desai
Priyank Desai
NHNafees Haider
Nafees Haider
VOVerner N Orish
Verner N Orish
Sanyaolu A, et al. Clin Exp Vaccine Res. 2022 Jan;11(1):104-115. https://doi.org/10.7774/cevr.2022.11.1.104